Published 6 issues per year
ISSN Print: 1040-8401
ISSN Online: 2162-6472
Indexed in
Genetically Engineered Natural Killer Cells as a Means for Adoptive Tumor Immunotherapy
ABSTRACT
Natural killer (NK) cells are lymphoid cells of the innate immune system; they stand at the first defense line against viruses and transformed cells. NK cells use an array of germline-encoded activating and inhibitory receptors that sense virus-infected cells or malignant cells displaying altered surface expression of activating and inhibitory NK cell ligands. They exert potent cytotoxic responses to cellular targets and thus are candidate effector cells for immunotherapy of cancer. In particular, the genetic engineering of NK cells with chimeric antigen receptors (CARs) against surface-expressed tumor-associated antigens (TAAs) seems promising. In the allogeneic context, gene-modified NK cells compared to T cells may be superior because they are short-lived effector cells and do not cause graft-versus-host disease. Furthermore, their anti-tumoral activity can be augmented by combinatorial use with therapeutic antibodies, chemotherapeutics, and radiation. Today, efforts are being undertaken for large-scale NK-cell expansion and their genetic engineering for adoptive cell transfer. With the recent advances in understanding the complex biological interactions that regulate NK cells, it is expected that the genetic engineering of NK cells and a combinatorial blockade of immune evasion mechanisms are required to exploit the full potential of NK-cell-based immunotherapies.
-
Matosevic Sandro, Viral and Nonviral Engineering of Natural Killer Cells as Emerging Adoptive Cancer Immunotherapies, Journal of Immunology Research, 2018, 2018. Crossref
-
Varani , Auletta , Signore , Galli , State of the Art of Natural Killer Cell Imaging: A Systematic Review, Cancers, 11, 7, 2019. Crossref
-
Agrawal Vaibhav, Gbolahan Olumide B., Stahl Maximilian, Zeidan Amer M., Zaid Mohammad Abu, Farag Sherif S., Konig Heiko, Vaccine and Cell-based Therapeutic Approaches in Acute Myeloid Leukemia, Current Cancer Drug Targets, 20, 7, 2020. Crossref
-
Yilmaz Ahmet, Cui Hanwei, Caligiuri Michael A., Yu Jianhua, Chimeric antigen receptor-engineered natural killer cells for cancer immunotherapy, Journal of Hematology & Oncology, 13, 1, 2020. Crossref
-
Lupo Kyle, Matosevic Sandro, Immunometabolic targeting of NK cells to solid tumors, in Successes and Challenges of NK Immunotherapy, 2021. Crossref
-
Shokouhifar Alireza, Firouzi Javad, Nouri Masoumeh, Sarab Gholamreza Anani, Ebrahimi Marzieh, NK cell upraise in the dark world of cancer stem cells, Cancer Cell International, 21, 1, 2021. Crossref
-
Murad Shafiq, Michen Susanne, Becker Alexander, Füssel Monika, Schackert Gabriele, Tonn Torsten, Momburg Frank, Temme Achim, NKG2C+ NK Cells for Immunotherapy of Glioblastoma Multiforme, International Journal of Molecular Sciences, 23, 10, 2022. Crossref